Markus A. Ott is a Global Medical Technology Professional with more than twenty years successful experience in international/global commercial & non-commercial roles he has become a highly effective and creative industry leader with extensive knowledge of the healthcare market.

In recent past he lead the Global Market Access & Health Policy department at Roche Diagnostics International (CPS) and has been Global Innovation Lead for Foundation Medicine based in Switzerland. Last but not least was/is leading EMEA efforts of a highly innovative company in the Med Device space (Novocure) offering an innovative therapy in the area of brain and lung cancer. He established (opened up) the team in multiple European countries with a strong focus on implementation efforts (lead evaluations with local authorities and contract negotiations with insurance companies, etc.).

His passion are all aspects of his job but primarily Value Based Healthcare & the digitalization of our industry.

He is/has been a member of global Management teams for various companies and associations. So, Markus has been member of the Executive Board of MedTech Europe as well as the Swiss Diagnostic Association. He acted as Chair Elect and Executive Board Member of EPPOSI (European Platform for Patient's Organizations, Science & Industry). Until 2021 he chaired the HTA IVD & Value of Diagnostics Working groups @ MedTech Europe.

Finally, he is author of multiple publications as well as chair, panelist and speaker at many global conferences.

Berit Dahl is a market and business insights manager for Smith & Nephew in the Europe and Canada region. This role supports the decision-making process on strategic commercial projects. She works for 5 years in the MedTech industry and collected extensive experience as finance business partner for the sales and marketing organisations in B2C and B2B environment of FMCG and Food before. The driver for
work is the continuously striving for better insights in the decision-making process for
all participants. Berit received a diploma in business informatics and holds an MBA in International Management. She is German and currently lives in Switzerland.

Graduated in 1987 as Electro-Mechanical Engineer with specialty electronics at the Catholic University of Leuven,  followed by a post-graduate year of Master of Business Administration. A first working experience in the field of Clinical Engineering at Intermedics, a US based pacemaker and implantable defibrillator company. Build out and directed the European Clinical Research Department. Holder of 5 patents in field of cardiac stimulation in health failure and co-author of 3 publication in this period. Joined in 1999 Medtronic to head the European Heart Failure clinical outcomes & research department ensuring the development of Clinical and Health Economic Outcome Evidence. In close cooperation with Clinical Community landmark trials were designed, conducted and published  in the Int’l journals as New England Journal of Medicine, Circulation and others with a high impact factor. A contribution of to 8 publication of which 3 as co-author. This evidence based ensured : Cardiac Resynchronization therapy obtained a class I indication level of evidence A in clinical guidelines; Cardiac Resynchronization therapy obtained a positive HTA appraisals for the full population studied . In September 2008, took on the responsibility of Assistant Director Health Economics, EurMEA at Alcon in the field of Ophthalmology for both medicinal and medical devices ranging from treatments of bacterial conjunctivitis, dry eye and glaucoma to Implantable Ocular Lenses. Developed comprehensive Patient Report Outcomes instrument to support patient diagnosis and assessing the outcome value of dry eye treatment to patients. Supported and co-authored to an additional 8 publications. As of 1st May 2012, head of Market Access and Economic Policies for  MEDTECH EUROPE to strive to balanced pro-innovation policies and to shift to a Value based Access model within EU frameworks.  Initiatives in dialogue with  procurers, payer, HTA member states representatives and other stakeholders are MEAT Value Based Procurement, Value of Diagnostic Information,  Modern HTA Cooperation in Europe,  new evidence and financing schemes to shift to access of medical technologies of value for patients, healthcare, society and our economy.

My name is Dr. Frank Semrau, I was born and went to school in the northern part of Germany (Lüneburg near Hamburg). I studied Biology in Göttingen and got the Diploma in Biology (Biochemistry, Microbiology) at the Georg-August University of Göttingen. I conducted my thesis at the University Hospital of Göttingen, Center for Hygiene and Human Genetics and got a PhD from Georg-August University of Göttingen (Biochemistry, Medical Microbiology), as well.

I started my business career at, then, one of the 10 biggest pharmaceutical companies Pharmacia which merged with Pfizer some years later, as a Regional Manager Health Politics, dealing with Associations of Statutory Health Insurance Physicians which control ambulatory prescriptions of pharmaceuticals.
In 2004 the DRG system was introduced in Germany and I attended and supported the implementation as a Manager Health Economics/Government Affairs with Boston Scientific (Medical devices) for almost nine years, the last years as a department deputy. While I started with responsibility for all products, with growing department I specialized in vascular and cardiac medical technologies like stents, ICDs and pacemaker.
Since 2012 I am with ZOLL CMS as a Strategic Reimbursement Manager for European countries. I am responsible for European market access and reimbursement of the wearable cardioverter defibrillator (WCD) “LifeVest” with a strong focus on Germany. From this point of view I have a very broadly defined idea of MA & Reimbursement, including preparation and optimization of reimbursement applications and coding, as well as initiating support by physicians, clinical studies, guidelines, patient organizations, health economic assessments and models, HTAs, pricing, politics, PR and social opinion. Currently my main goal is the seamless protection of patients with high risk for sudden cardiac death (SCD) in and particularly outside the hospital.

Being a marketing expert with over a decade of international experience in the medical device industry, Franziska Preissing has been able to gather extensive experience, particularly in the field of introducing innovative products and therapies into intensive care and cardiac surgery. In the position of International Marketing Director of several medical device companies, as well working as a consultant, she has, over the years, acquired profound knowledge on reimbursement strategies and health economics, with a focus on how to proceed as a small and medium sized enterprise. Today Franziska Preissing is responsible for global reimbursement strategies and health economics at CytoSorbents Europe, who launched the CytoSorb adsorber, an extracorporeal therapy that enables innovative adsorption in SIRS (systemic inflammatory response syndrome) and sepsis patients.

Nicolas holds a Master in Business from ESSEC (2008) and a master in History from the Sorbonne University in Paris (2005).

Having started as a consultant for Izsak Grapin & Associés in 2006 where he worked noticeably for ROCHE Pharma, he joined the Consumer Products division of L’OREAL in 2010 as a territory Manager to develop sales through the structuring and the optimization of the local distribution network. In 2012, he integrated L’OREAL Marketing team in Paris to reinforce the Matrix haircare brand in France.

After 2 years with Septodont where he managed and developed the international distribution network in the CIS Countries, he joins Echosens in 2017 where he currently works as International Sales Director for Italy, Central Europe, Russia and Eurasia.

Tove is a professor of health economic evidence at the University of Ghent.

Tove has more than 20 years pharmaceutical experience in the field of health economics, outcome research, and evidence based documentation of health improvements. 

Stephen Hull is Principal and Founder of Hull Associates LLC, a specialized global reimbursement and market access consultancy. He and his firm leverage over 25 years of experience in US and global reimbursement and in-market expertise on behalf of pharma, medical device and diagnostics Clients. Prior to forming Hull Associates in 2007, he served as SVP for Global Reimbursement at AdvaMed, in Washington, D.C. and as chair of the ISPOR Medical Devices Council. Stephen holds a Master’s degree in health policy from the Johns Hopkins Bloomberg School of Public Health, and a bachelor’s degree in international relations and French from Colgate University.

Ernesto is the Founder and Managing Director of ValueConnected. He has over 23

years of experience leading healthcare strategies to drive access and expansion for new products, developing value propositions for both public and private stakeholders and assessing global market opportunities. He has worked for both government agencies and global healthcare companies in roles ranging from strategic marketing and new product development to health economics and reimbursement. Ernesto has led several Market Access projects across Europe, US, Middle East and Latin America. Ernesto holds an MBA from the University of Texas at Austin and is fluent in English, Spanish and Portuguese.